Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union Read more about Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Amgen Statement on European Investor Visit Read more about Amgen Statement on European Investor Visit
Amgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering Read more about Amgen Announces Plan to Launch Tender Offer and Launch of Senior Notes Offering
Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease Read more about Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active Disease
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial Read more about Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture Trial
Amgen's Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40 Read more about Amgen's Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
Amgen Announces Webcast of 2011 Third Quarter Financial Results Read more about Amgen Announces Webcast of 2011 Third Quarter Financial Results
Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations Read more about Amgen Appoints Anthony (Tony) Hooper Executive Vice President Global Commercial Operations
Amgen Appoints Robert A. Bradway to the Company's Board of Directors Read more about Amgen Appoints Robert A. Bradway to the Company's Board of Directors
Amgen Announces 2011 Fourth Quarter Dividend Read more about Amgen Announces 2011 Fourth Quarter Dividend
